Sanofi says Zaltrap cancer drug study positive
PARIS (Reuters) - French drugmaker Sanofi said on Monday that the results of a late-stage study of its Zaltrap drug showed a "statistically significant improvement in overall survival" in patients with colon cancer.
The detailed results of the Phase III study of the drug used in conjunction with chemotherapy were published in the October edition of the Journal of Clinical Oncology, Sanofi said in a statement.
Zaltrap, also known as aflibercept, is a so-called anti-angiogenic agent, designed to starve tumors of blood.
- Exclusive: Radar data suggests missing Malaysia plane deliberately flown way off course - sources
- Investigators focus on foul play behind missing Malaysia plane: sources |
- Kremlin website hit by 'powerful' cyber attack
- West prepares sanctions as Russia presses on with Crimea takeover |
- UPDATE 1-Rolls-Royce concurs with Malaysia on missing jet's engine data